uniQure (QURE) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and uniQure published the results on November 4, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison.

• uniQure N.V. is a Dutch company but files U.S. domestic forms (10-Q and 10-K) and reports in U.S. dollars.
• Q4 2025 revenue is derived: the 2025 annual figure from the Q4 2025 release minus nine-month 2025 revenue. That release gives no fourth-quarter EPS.

Source: uniQure Q3 2026 results, November 4, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How uniQure splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• uniQure's License revenues revenue was $5.2 million in Q3 2026, up 45% from $3.6 million in Q3 2025, 100% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

uniQure gives no revenue or EPS outlook. Its release gives a cash runway.

In its Q3 2026 release, uniQure said:

“The Company expects that these resources will be sufficient to fund projected operating expenses into 2030.”

Source: uniQure Q3 2026 release (Form 8-K, Exhibit 99.1), Nov 4, 2026.

This is the company's own guidance as of Nov 4, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the QURE forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP total revenues and basic and diluted net loss per ordinary share, each as first reported in that quarter's release. Q4 2025 revenue is 2025 annual revenue ($16.1 million) minus nine-month revenue ($10.5 million); uniQure's Q4 2025 release reports full-year figures only, so Q4 EPS is not shown.

We do not hold a confirmed date for uniQure's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 4, 2026

uniQure's revenue is royalties on HEMGENIX, the hemophilia B gene therapy it licensed to CSL Behring. In Q3 2026 all $5.2 million of revenue was license revenue, which uniQure recognizes from royalty payments CSL Behring owes on HEMGENIX sales, against $3.6 million of license revenue and $119 thousand of collaboration revenue in Q3 2025. (uniQure Form 10-Q, Q3 2026, Nov 4, 2026)

Total revenue was $5.2 million, against $3.7 million a year earlier, and uniQure said the $1.5 million increase was due to higher license revenue. Over the first nine months of 2026 revenue was $14.6 million, against $10.5 million in the same period of 2025. (uniQure Q3 2026 release, Nov 4, 2026; uniQure Form 10-Q, Q3 2026, Nov 4, 2026)

uniQure does not keep all of that royalty stream. In 2023 it received a $375.0 million upfront payment for the rights to the lowest royalty tier on CSL Behring's worldwide net sales of HEMGENIX, and it carries that Royalty Financing Agreement as a liability of $497.3 million at September 30, 2026, up from $473.2 million at December 31, 2025. Interest expense on it was $13.2 million in the quarter. Receivables from CSL Behring, all royalty-related, were $4.8 million. (uniQure Form 10-K, 2025, Mar 2, 2026; uniQure Form 10-Q, Q3 2026, Nov 4, 2026)

uniQure's first potential product revenue of its own is AMT-130 (ifezuntirgene inilparvovec) for Huntington's disease. The FDA accepted its Biologics License Application under the Accelerated Approval pathway with Priority Review and a PDUFA target action date of May 1, 2027, and the U.K. MHRA validated a Marketing Authorization Application in the quarter. (uniQure Q3 2026 release, Nov 4, 2026)

uniQure reports GAAP EPS only. Its net loss was $61.2 million, or $0.88 per ordinary share, in Q3 2026, against $80.5 million, or $1.38, a year earlier. Research and development expense rose to $35.5 million from $34.4 million, and selling, general and administrative expense rose to $23.9 million from $19.4 million as uniQure recruited staff for a potential AMT-130 launch. (uniQure Q3 2026 release, Nov 4, 2026)

The smaller loss came mostly below the operating line. Non-operating items were a net expense of $7.6 million, against $20.9 million, because of a $6.3 million reduction in pre-funded warrant expenses and $6.8 million more net interest income. Interest income was $8.1 million, against $3.5 million. Income tax expense fell to $676 thousand from $8.6 million. (uniQure Q3 2026 release, Nov 4, 2026; uniQure Form 10-Q, Q3 2026, Nov 4, 2026)

Share issuance also lowered the per-share loss. Weighted average shares were 69,900,863, against 58,516,415 in Q3 2025. Over the first nine months of 2026 uniQure sold 5,686,813 ordinary shares in a follow-on public offering for $242.7 million and issued 526,314 shares on exercise of pre-funded warrants. (uniQure Q3 2026 release, Nov 4, 2026; uniQure Form 10-Q, Q3 2026, Nov 4, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

uniQure gives no revenue or EPS outlook. Its release says cash, cash equivalents and investment securities of $768.4 million at September 30, 2026, against $622.5 million at December 31, 2025, are expected to fund projected operating expenses into 2030. (uniQure Q3 2026 release, Nov 4, 2026)

The dates uniQure names are the AMT-130 PDUFA date of May 1, 2027; patient screening for a confirmatory study of approximately 200 patients, beginning in the U.S. by the end of 2026; and updated results for AMT-260 in epilepsy and AMT-191 in Fabry disease in the first half of 2027. In July 2026 uniQure extended the window to draw a $100.0 million Hercules term loan tranche to September 30, 2027. (uniQure Q3 2026 release, Nov 4, 2026; uniQure Form 10-Q, Q3 2026, Nov 4, 2026)

A consensus figure is the average of the models published by the analysts who cover uniQure, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones uniQure's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning QURE is on is QURE a buy or a sell?, what analysts expect next is on the QURE forecast, and what the company does is on the uniQure (QURE) stock page.

Every number on this page can be traced to a document uniQure published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.